Clinical Trials in China / NCT06614179
Recruiting
Observational
A Pan-cancer Screening and Diagnosis Model Based on Abdominal CT Was Established
NCT06614179 · tracked via the Priya Life Science China tracker
Condition(s) studied
Abdominal Neoplasm
Study summary
Abdominal noncontrast scan and contrast-enhanced CT were used to establish a screening and diagnostic model for abdominal tumors
Eligibility
Inclusion Criteria:
* Patients with abdominal tumors:
* all patients were pathologically diagnosed with abdominal tumors;
* The clinical case data of all patients were complete, and complete follow-up was obtained, with clear information on medical visits, operation time and survival status within 2 years. If the cause of death is unknown, it will be recorded as censored data;
* All patients had no history of active abdominal bleeding, no serious infection or other abdominal diseases that affected the observation of CT imaging within 3 months before surgery.
* Non-tumor population:
* all patients have complete clinical case data, complete abdominal CT, no history of malignant tumors, no serious infections or other abdominal diseases that affect the diagnosis and observation of CT imaging.
Exclusion Criteria:
* Cases in which contrast-enhanced or noncontrast CT images show unclear lesions, with significant noise and artifacts;
Primary outcome measure(s)
- Whether or not there is a diagnosis of abdominal tumor questionnaire — first visited at baseline
Whether or not there is a diagnosis of abdominal tumor
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) | Hangzhou | Zhejiang | Recruiting |
| Zhejiang Cancer Hospital;Cancer hospital of the university of chinese academy of sciences | Hangzhou | Zhejiang | Recruiting |
More Xiangdong Cheng trials in China
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06614179 on ClinicalTrials.gov ↗ ← All trials in China